Pharma — India Patent Cases
730 decisions indexed
Page 18 of 25 · 730 total
Chugai Seiyaki Kabushiki Kaisha v.MSN Laboratories Private Limited
The plaintiffs filed a suit seeking an ad interim injunction against MSN Laboratories Private Limited for infringing Indian Patent No. IN 294424, which covers Alectinib or its derivatives. The court allowed the application subject to exceptions, permitting the defendant to use the drug for research purposes under Section 107A of the Patents Act, but prohibiting commercial launch without prior court permission.
Sun Pharmaceuticals Industries Ltd v.Union Of India & Ors.
Sun Pharmaceuticals Industries Ltd filed a writ petition seeking directions for the expeditious disposal of opposition proceedings against Patent No. 257402, which was granted to Novo Nordisk A/S. The court addressed the procedural delay and directed the respondents to furnish the Opposition Board's recommendations within one week, subsequently rescheduling the hearing.
Novo Nordisk A/S v.Union Of India & Ors.
Novo Nordisk A/S filed a petition seeking a writ of mandamus to compel Respondent Authorities (No. 1 through No. 3) to decide on its request for the cross-examination of witnesses in a pending post-grant opposition against Patent No. IN 257402. The court, after considering arguments from both sides, directed that Respondent No. 2 fix the date for the cross-examination and complete it expeditiously.
Bristol-Myers Squibb Ireland Unlimited Company v.Micro Labs Limited
The plaintiffs filed a suit seeking permanent injunction against Micro Labs Limited for infringing their registered patent (No. 247381) related to Apixaban, an anticoagulant drug. The court considered the prior history of similar cases and granted an ex-parte ad- interim injunction restraining the defendant from manufacturing or selling generic Apixaban under any brand name, including 'APIVAS'.
Novartis Ag v.Msn Laboratories Pvt Ltd
The plaintiff, Novartis AG, seeks to restrain the defendant from manufacturing Pazopanib Hydrochloride, claiming it infringes their Indian patent. The defendant has obtained approval to manufacture the product, raising concerns of imminent patent infringement.
F.Hoffmann-La Roche Ltd. v.Matrix Laboratories Limited
F.Hoffmann-La Roche Ltd. filed a suit seeking permanent injunction against Matrix Laboratories Limited for infringing Indian Patent No.196774, which relates to a pharmaceutical or chemical compound product. The court ultimately disposed of the suit as no further orders were necessary due to the rejection of leave to institute the suit by the Division Bench.
Novartis Ag & Anr. v.Assistant Controller Of Patents And Designs
Novartis Ag & Anr. filed an appeal challenging the Assistant Controller's refusal to grant their Indian Patent Application No. 10611/DELNP/2015. The court allowed an interlocutory application regarding document filing and issued notice to the Defendant, setting the matter for further hearing.
Indiyaa Distribution Network Llp v.P Singh & Ors.
The Delhi High Court granted an ad-interim injunction in favor of Indiyaa Distribution Network Llp against P Singh & Ors. The Plaintiff, a prior user of the Ayurvedic joint pain relief oil 'SANDHI SUDHA', successfully argued that the Defendants' use of similar marks and imitation of packaging constituted passing off and copyright infringement. The court recognized the Plaintiff's established market presence and sales history to protect consumers from potential confusion.
Sandeep Pandey v.Union Of India And 4 Others
The petitioner filed a PIL seeking directions for the vaccination of citizens between the ages of 18 and 45, and also sought directions under the Patents Act, 1970, to acquire necessary patents for vaccine manufacturing. The court dismissed the petition as the issue was pending before the Apex Court.
Merck Sharp And Dohme Corp. v.Sms Pharmaceuticals Limited
Merck Sharp And Dohme Corp. filed a suit seeking an injunction against Sms Pharmaceuticals Limited for infringing its patent on Sitagliptin, an anti-diabetic drug. The court initially granted an ex-parte ad interim injunction in favor of Merck. However, upon considering the defendant's request under Section 107A (Bolar exemption), the court modified the injunction to allow limited export of the API for research and development purposes.
Astrazeneca Ab v.Intas Pharmaceuticals Limited, Alkem Laboratories Ltd., Zydus Healthcare Limited & Anr., Torrent Pharmaceuticals Limited, Micro Labs Limited, MSN Laboratories Private Limited, Eris Lifesciences Limited, USV Private Limited, Ajanta Pharma Limited
This Delhi High Court judgment addresses multiple appeals filed by AstraZeneca seeking interim relief to restrain various pharmaceutical companies from infringing its patents. The core issue revolved around whether AstraZeneca was entitled to an immediate injunction while the underlying suits for permanent injunction were pending. The court ultimately dismissed all nine appeals, finding no merit in the appellants' claims.
Ms. Mallika Singh Daughter Of Mr. Narendra Singh and Mr. Parth Pareek Son Of Mr. Prem Prakash Pareek v.Union Of India, State Of Rajasthan, Principal Secretary, Department Of Medical, Health And Family Welfare, Government Of Rajasthan
Petitioners filed a Public Interest Litigation seeking directions to the respondents to ascertain if any vaccine is covered by patents, issue compulsory licenses under the Patents Act, share manufacturing trade secrets, and increase vaccine production capacity. The court dismissed the petition, stating that the issues involved relate to policy decisions to be taken by the respondents.
H. Lundbeck A/S v.Symed Labs Limited
The dispute concerned the alleged infringement of Indian Patent No. 227963 by Symed Labs Limited regarding Vortioxetine/Vortioxetine Hydrobromide. The parties amicably resolved the matter, leading to a decree in terms of the settlement agreement.
Merck Sharp And Dohme Corp v.Amoli Organics Private Limited
Merck Sharp And Dohme Corp filed a suit seeking a permanent injunction and damages against Amoli Organics Private Limited for allegedly making, selling, or dealing in products that infringe its Indian Patent No 209816. The dispute centered on the Sitagliptin API and its salts.
Merck Sharp And Dohme Corp v.Solitaire Pharmacia Private Limited
The plaintiffs filed for an ex-parte injunction against the defendants for infringing their Indian Patent No. 209816 related to SITAGLIPTIN and its pharmaceutically acceptable salts. The court found a prima facie case in favor of the plaintiffs.
Merck Sharp And Dohme Corp v.Yms Laboratories Private Limited
The plaintiffs allege that the defendant is infringing their Indian Patent No. 209816 related to SITAGLIPTIN. They seek an injunction to prevent the defendant from manufacturing or selling infringing products.
Natco Pharma Limited v.Union Of India & Ors.
Natco Pharma Limited filed a writ petition challenging the procedural approach of the Patent Controller, arguing that its application for cross-examination of expert witnesses had not been decided. The court observed the long pendency and directed the Controller to first dispose of Natco's cross-examination application before proceeding with the merits of Novartis' patent application.
Dharmendra Kumar Aggarwal v.Govt. Of Nct Of Delhi Through The Secretary & Anr.
This petition addressed the critical issue of supply and availability of the drug Tocilizumab 400 MG (Actemra) for COVID-19 patients in Delhi. The court examined submissions from Roche India, which indicated that global demand far exceeded current manufacturing capabilities. While Roche mentioned partnerships with other entities to meet demand, they provided no clear assurance regarding further supply to India. Consequently, the court issued detailed directions to both Roche and the Union of India to provide comprehensive affidavits on supply chain status, patent details, and potential alternatives.
Centaur Pharmaceuticals Pvt Ltd v.Mhs Pharmaceuticals Pvt Ltd
Centaur Pharmaceuticals filed an Interim Application against MHS Pharmaceuticals. The court noted that the dispute was complex and did not meet the criteria for an immediate ad-interim order, requiring a final hearing after both parties submitted additional evidence.
Pfizer Products Inc v.Unichem Laboratories Limited
The Plaintiffs filed a suit for permanent injunction against the Defendant for infringement of Indian Patents. The parties reached a settlement and withdrew the suit and counter-claim.
Novartis Ag v.Windlas Biotech Pvt Ltd
The case involves a patent infringement dispute where Novartis AG claims that Windlas Biotech Pvt Ltd is infringing on their Indian Patent No. 229051 related to a pharmaceutical composition comprising Sacubitril + Valsartan. The court has previously issued an interim order restraining the defendants from using the infringing product.
Novartis Ag v.Eris Lifesciences Limited
The case involves a patent infringement dispute where Novartis AG claims that Eris Lifesciences Limited is infringing on their Indian Patent No. 229051 related to a pharmaceutical composition comprising Sacubitril + Valsartan.
H. Lundbeck A/S v.Hetero Drugs Limited
The suit sought an injunction against Hetero Drugs Limited concerning Indian Patent 227963 for Vortioxetine Hydrobromide. The parties reached a settlement regarding IA No. 2333/2021, allowing the defendant to export products under Section 107A of the Patents Act, provided strict conditions are met.
Merck Sharp And Dohme Corp v.Indilina Pharmaceuticals
Merck Sharp & Dohme Corp (Plaintiff) filed a suit seeking an injunction against Indilina Pharmaceuticals (Defendant) for infringing their patent (IN'816) covering the compound Sitagliptin. The Plaintiffs alleged that the Defendant was offering tablets of Sitagliptin for sale in tenders. The Court granted interim relief restraining the Defendant from any infringing activities and directed disclosure of profits.
Novartis Ag v.Eris Lifesciences Limited
The plaintiffs seek an injunction to restrain the defendant from manufacturing and selling a pharmaceutical composition that allegedly infringes their patent.
H. Lundbeck A/S v.Hetero Drugs Limited
The dispute involves H. Lundbeck A/S challenging Hetero Drugs Limited's export activities, which are claimed by the defendants to be permissible under Section 107A of the Patents Act for R&D purposes. The court issued an interim order allowing the defendants to continue exports to seven specified entities while addressing objections raised by the plaintiff.
H. Lundbeck A/S v.Hetero Drugs Limited
H. Lundbeck A/S filed a suit against Hetero Drugs Limited regarding alleged infringement of Patent IN227963, which covers Vortioxetine Hydrobromide. During the hearing, the defendants asserted that they were not commercially launching any product and were using the substance solely for regulatory and R&D purposes.
Merck Sharp And Dohme Corp & Anr v.Actis Generics Pvt Ltd
The Plaintiffs, Merck Sharp & Dohme Corp. and Sun Pharmaceutical Industries Ltd., filed a suit seeking an injunction against Actis Generics Pvt Ltd for infringing Patent No. IN'816, which covers the compound Sitagliptin. The court examined the prima facie case and found that the Defendant was distributing and selling infringing Sitagliptin API without authorization.
Eli Lilly And Company v.Natco Pharma Limited
This case involved a suit for alleged patent infringement. The defendants filed applications seeking condonation of delay in filing their written statements, citing difficulties caused by the COVID-19 pandemic and general disruptions to legal processes. The court allowed these applications, condoning the delay.
Astrazeneca Pharma India Limited v.The National Pharmaceutical Pricing Authority & Ors.
Astrazeneca challenged several orders and notifications issued by NPPA regarding overcharging on its drug, OSIMERTINIB (TAGRISSO). The petitioner argued that the drug is patented and qualifies for a five-year exemption from price controls under DPCO, 2013. The Court directed NPPA to reconsider the matter afresh after taking into account the data supplied by the petitioner.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.